Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC; ISIS-396443-CS2/ISIS-396443-CS12 Study Groups.

Neurology. 2019 May 21;92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527. Epub 2019 Apr 24.

2.

Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

Bartlett A, Kolb SJ, Kingsley A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Coffey CS, Yankey JW, Cudkowicz ME, McGovern MM, McNeil DE, Arnold WD, Kissel JT; NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.

Contemp Clin Trials Commun. 2018 Jul 20;11:113-119. doi: 10.1016/j.conctc.2018.07.002. eCollection 2018 Sep.

3.

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group.

N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.

4.

Natural history of infantile-onset spinal muscular atrophy.

Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators.

Ann Neurol. 2017 Dec;82(6):883-891. doi: 10.1002/ana.25101. Epub 2017 Dec 8.

5.

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group.

N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.

6.

Nusinersen for the treatment of spinal muscular atrophy.

Chiriboga CA.

Expert Rev Neurother. 2017 Oct;17(10):955-962. doi: 10.1080/14737175.2017.1364159. Epub 2017 Sep 8. Review.

PMID:
28884620
7.

Zika Virus-Associated Cognitive Impairment in Adolescent, 2016.

Zucker J, Neu N, Chiriboga CA, Hinton VJ, Leonardo M, Sheikh A, Thakur K.

Emerg Infect Dis. 2017 Jun;23(6):1047-1048. doi: 10.3201/eid2306.162029.

8.

Phenotype of GABA-transaminase deficiency.

Koenig MK, Hodgeman R, Riviello JJ, Chung W, Bain J, Chiriboga CA, Ichikawa K, Osaka H, Tsuji M, Gibson KM, Bonnen PE, Pearl PL.

Neurology. 2017 May 16;88(20):1919-1924. doi: 10.1212/WNL.0000000000003936. Epub 2017 Apr 14. Review.

9.

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.

Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM.

Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7.

PMID:
27939059
10.

Six-minute walk test is reliable and valid in spinal muscular atrophy.

Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, Chiriboga CA, Garber CE, De Vivo DC.

Muscle Nerve. 2016 Nov;54(5):836-842. doi: 10.1002/mus.25120. Epub 2016 May 13.

PMID:
27015431
11.

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.

Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT; NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.

Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45. doi: 10.1002/acn3.283. eCollection 2016 Feb.

12.

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.

Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM.

Neurology. 2016 Mar 8;86(10):890-7. doi: 10.1212/WNL.0000000000002445. Epub 2016 Feb 10.

13.

Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy.

Montes J, Glanzman AM, Mazzone ES, Martens WB, Dunaway S, Pasternak A, Riley SO, Quigley J, Pandya S, De Vivo DC, Kaufmann P, Chiriboga CA, Finkel RS, Tennekoon GI, Darras BT, Pane M, Mercuri E, Mcdermott MP; Pediatric Neuromuscular Clinical Research Network, Muscle Study Group, SMA Europe.

Muscle Nerve. 2015 Dec;52(6):942-7. doi: 10.1002/mus.24670. Epub 2015 Oct 10.

PMID:
25846132
14.

Neurobehavioral and Developmental Traiectories Associated with Level of Prenatal Cocaine Exposure.

Chiriboga CA, Kuhn L, Wasserman GA.

J Neurol Psychol. 2014 Nov;2(3). pii: 12.

15.

Identification of a novel nemaline myopathy-causing mutation in the troponin T1 (TNNT1) gene: a case outside of the old order Amish.

Marra JD, Engelstad KE, Ankala A, Tanji K, Dastgir J, De Vivo DC, Coffee B, Chiriboga CA.

Muscle Nerve. 2015 May;51(5):767-72. doi: 10.1002/mus.24528. Epub 2015 Feb 17.

PMID:
25430424
16.

Leg muscle function and fatigue during walking in spinal muscular atrophy type 3.

Montes J, Dunaway S, Garber CE, Chiriboga CA, De Vivo DC, Rao AK.

Muscle Nerve. 2014 Jul;50(1):34-9. doi: 10.1002/mus.24081. Epub 2014 May 5.

PMID:
24122959
17.

Reduction in upper-extremity tone after lumbar selective dorsal rhizotomy in children with spastic cerebral palsy.

Gigante P, McDowell MM, Bruce SS, Chirelstein G, Chiriboga CA, Dutkowsky J, Fontana E, Hyman J, Kim H, Morgan D, Pearson TS, Roye BD, Roye DP Jr, Ryan P, Vitale M, Anderson RC.

J Neurosurg Pediatr. 2013 Dec;12(6):588-94. doi: 10.3171/2013.9.PEDS12591. Epub 2013 Oct 11.

PMID:
24116982
18.

Weakness and fatigue in diverse neuromuscular diseases.

Montes J, Blumenschine M, Dunaway S, Alter AS, Engelstad K, Rao AK, Chiriboga CA, Sproule DM, De Vivo DC.

J Child Neurol. 2013 Oct;28(10):1277-83. doi: 10.1177/0883073813493663. Epub 2013 Jul 11.

PMID:
23847297
19.

Facial palsy and idiopathic intracranial hypertension in twins with cystic fibrosis and hypovitaminosis A.

Obeid M, Price J, Sun L, Scantlebury MH, Overby P, Sidhu R, Chiriboga CA, Quittell LM.

Pediatr Neurol. 2011 Feb;44(2):150-2. doi: 10.1016/j.pediatrneurol.2010.10.002.

PMID:
21215918
20.

Subclinical seizures in children diagnosed with localization-related epilepsy: clinical and EEG characteristics.

Akman CI, Montenegro MA, Jacob S, Eck K, McBrian D, Chiriboga CA, Patterson MC.

Epilepsy Behav. 2009 Sep;16(1):86-98. doi: 10.1016/j.yebeh.2009.06.026. Epub 2009 Jul 25.

PMID:
19632903
21.

Prenatal cocaine exposure and prolonged focus attention. Poor infant information processing ability or precocious maturation of attentional systems?

Chiriboga CA, Starr D, Kuhn L, Wasserman GA.

Dev Neurosci. 2009;31(1-2):149-58. doi: 10.1159/000207502. Epub 2009 Apr 17.

PMID:
19372695
22.

The frequency of non-epileptic spells in children: results of video-EEG monitoring in a tertiary care center.

Montenegro MA, Sproule D, Mandel A, Cappell J, Chiriboga CA, Jacob S, Eck K, Patterson MC, Akman CI.

Seizure. 2008 Oct;17(7):583-7. doi: 10.1016/j.seizure.2008.02.010. Epub 2008 May 1.

23.

Prenatal cocaine exposures and dose-related cocaine effects on infant tone and behavior.

Chiriboga CA, Kuhn L, Wasserman GA.

Neurotoxicol Teratol. 2007 May-Jun;29(3):323-30. Epub 2006 Dec 8.

24.

Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART).

Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ.

J Pediatr. 2005 Mar;146(3):402-7.

PMID:
15756229
25.
26.

Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.

Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC.

Neurology. 2004 Apr 13;62(7):1058-65. Review.

PMID:
15079002
27.
28.

Factors associated with microcephaly at school age in a very-low-birthweight population.

Chiriboga CA, Kuban KC, Durkin M, Hinton V, Kuhn L, Sanocka U, Bellinger D.

Dev Med Child Neurol. 2003 Dec;45(12):796-801.

29.

Fetal alcohol and drug effects.

Chiriboga CA.

Neurologist. 2003 Nov;9(6):267-79. Review.

PMID:
14629781
30.

Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure.

Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA.

Pediatr Neurol. 2003 Aug;29(2):124-30.

PMID:
14580655
31.

Neonatal blood carnitine concentrations: normative data by electrospray tandem mass spectometry.

Chace DH, Pons R, Chiriboga CA, McMahon DJ, Tein I, Naylor EW, De Vivo DC.

Pediatr Res. 2003 May;53(5):823-9. Epub 2003 Feb 20.

PMID:
12612202
32.

Human Immunodeficiency Virus (HIV) in Children.

Chiriboga CA.

Curr Treat Options Neurol. 2002 May;4(3):213-224.

PMID:
11931728
33.

Intracerebral aneurysms in human immunodeficiency virus infection: case report and literature review.

Mazzoni P, Chiriboga CA, Millar WS, Rogers A.

Pediatr Neurol. 2000 Sep;23(3):252-5. Review.

PMID:
11033289
34.

Dose-response effect of cocaine on newborn head circumference.

Bateman DA, Chiriboga CA.

Pediatrics. 2000 Sep;106(3):E33.

PMID:
10969117
35.

Dose-response effect of fetal cocaine exposure on newborn neurologic function.

Chiriboga CA, Brust JC, Bateman D, Hauser WA.

Pediatrics. 1999 Jan;103(1):79-85.

PMID:
9917443
36.

Neurological correlates of fetal cocaine exposure.

Chiriboga CA.

Ann N Y Acad Sci. 1998 Jun 21;846:109-25. Review.

PMID:
9668401
37.

Neurological Correlates of Fetal Cocaine Exposurea.

Chiriboga CA.

Ann N Y Acad Sci. 1998 Jun;846(1):109-125. doi: 10.1111/j.1749-6632.1998.tb09730.x.

PMID:
29087564
38.

Massive intracranial arachnoid cyst in a developmentally normal infant: case report and literature review.

Mason TB 2nd, Chiriboga CA, Feldstein NA, Kartha K, Khandji AG.

Pediatr Neurol. 1997 Jan;16(1):59-62. Review.

PMID:
9044405
39.

Postinflammatory hydrocephalus and intracranial mass lesion from Candida in an immunocompetent child.

Mason TB 2nd, Chiriboga CA, Cargan AL, Hauger SB, La Russa PS, Glick RS, Carmel PW, Khandji AG, De Vivo DC.

J Child Neurol. 1996 Jul;11(4):336-41. No abstract available.

PMID:
8807425
40.

Neurological correlates of fetal cocaine exposure: transient hypertonia of infancy and early childhood.

Chiriboga CA, Vibbert M, Malouf R, Suarez MS, Abrams EJ, Heagarty MC, Brust JC, Hauser WA.

Pediatrics. 1995 Dec;96(6):1070-7.

PMID:
7491223
41.

Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine.

Moss W, Ojukwu C, Chiriboga CA.

Clin Pediatr (Phila). 1994 Oct;33(10):634-8. No abstract available.

PMID:
7813146
42.

Fetal effects.

Chiriboga CA.

Neurol Clin. 1993 Aug;11(3):707-28. Review.

PMID:
8377750
43.

Neurologic findings in neonates with intrauterine cocaine exposure.

Chiriboga CA, Bateman DA, Brust JC, Hauser WA.

Pediatr Neurol. 1993 Mar-Apr;9(2):115-9.

PMID:
8499039
44.

Chronic ACTH treatment increases striatal dopamine D-2 receptor binding in developing rat brain.

Chiriboga CA, Pranzatelli MR, De Vivo DC.

Brain Dev. 1989;11(3):197-200.

PMID:
2546461

Supplemental Content

Loading ...
Support Center